Typhoid fever due to multiresistant Salmonella enterica serovar typhi having reduced susceptibility to ciprofloxacin and nalidixic acid resistance.
Panhotra
Bodh R
BR
Department of Microbiology and Infection Control, King Fahad Hospital and Tertiary Care Center, Al-Hofuf, Al-Hasa 31982, Kingdom of Saudi Arabia. drpanhotra2000@yahoo.co.in
Saxena
Anil K
AK
Al-Ghamdi
Ali M
AM
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001774:Blood Chemical Analysis; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009268:Nalidixic Acid / Q000494:pharmacology*; D018570:Risk Assessment; D012485:Salmonella typhi / Q000187:drug effects* / Q000302:isolation & purification; D012494:Sampling Studies; D012529:Saudi Arabia; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014435:Typhoid Fever / Q000175:diagnosis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D009268:Nalidixic Acid; D002939:Ciprofloxacin